NCT05422885View on ClinicalTrials.gov

Safety and Feasibility of Dasatinib and Quercetin in Adults at Risk for Alzheimer's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

May 20, 2022

Primary Completion Date

January 24, 2024

Study Completion Date

January 24, 2024

Conditions
Aging
Interventions
DRUG

Dasatinib

Dasatinib 100 mg for 2 consecutive days, every two weeks for 12 weeks

DRUG

Quercetin

Quercetin 1,250 mg for 2 consecutive days, every two weeks for 12 weeks

Trial Locations (1)

02131

Hebrew Senior Life, Boston

All Listed Sponsors
lead

Lewis Lipsitz

OTHER